Cimerli Interchangeable Biosimilar Approved Without Switching Data
Coherus Ranibizumab Rival Will Compete With Lucentis And Byooviz In US
Citing low risk of a clinically impactful immunogenic response from systemic anti-drug antibodies and intraocular inflammation when alternating between Coherus’ Cimerli and Genentech’s reference product ranibizumab, US FDA says a switching study would not be informative.
